In this report, the market is segmented based on product, application, end user, and region. This report also discusses the key market drivers, restraints, opportunities, and challenges for this market and its submarkets.
The overall high content screening market is expected to grow from USD 506.7 million in 2016 to USD 909.0 million by 2022, at a CAGR of 10.3% from 2017 to 2022.
The conventional method of toxicity studies involves the screening of large libraries in search of potential drug candidates. This method is expensive, resource- & time-consuming, and has a low success rate.
Hence, HCS solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in vitro toxicity testing by reducing the time and cost. The need for cost containment in pharma R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market.
Prominent Players:
The prominent players in the global high-content screening market are GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).
Know latest Trends @ https://www.marketsandmarkets.com/Market-Reports/high-content-screening-market-42710391.html
